Why the study?
Does doxazosin reduce oxidative stress related proteins in essential hypertensive patients?
Does doxazosin reduce oxidative stress related proteins in essential hypertensive patients?
Doxazosin demonstrates an inhibitory effect on oxidative stress-related proteins at the molecular level in essential hypertension, suggesting potential antiatherosclerotic benefits.
May suggest antiatherosclerotic potential for doxazosin in hypertension; hypothesis-generating and requires randomized confirmation.
The role of oxidative stress in the pathophysiology of hypertension has stimulated the investigation of strategies to reduce oxidative stress via antioxidant defenses. Using a molecular biology approach, we report, in essential hypertensive patients, the effect of doxazosin treatment on the mononuclear cell gene and protein expression of two major elements in the oxidative stress and vascular remodeling-related pathways: p22(phox) and PAI-1. Ten essential hypertensive patients were treated with Doxazosin (4 mg/day) for two weeks (EH + D) and compared with ten untreated hypertensive patients (EH) and ten normotensive subjects (C). In EH p22(phox) and PAI-1 mRNA and protein level was increased compared with C. In EH + D, doxazosin reduced p22(phox) and PAI-1 gene and protein expression, which was similar to that of C. These results demonstrate for doxazosin an inhibitory effect on oxidative stress related proteins at gene and protein level, which confirms at molecular level a powerful antioxidant potential for this agent that could translate, in the long term, into a powerful antiatherosclerotic effect.
No takes yet. Share an insight, caveat, or question.
Calò et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: